CoChat

Pioglitazone initiation and subsequent hospitalization for congestive heart failure

Open access
Karter, A. J., Ahmed, A. T., Liu, J., Moffet, H. H., Parker, M. M. · 2005 · Diabetic Medicine
Cited by 90

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Aims Thiazolidinediones (TZD) have been associated with an expansion in plasma volume and the development of peripheral oedema. A recent study reported an association between the use of TZDs and development of congestive heart failure (CHF). The objective of this study was to determine if short‐term use of pioglitazone, a TZD, is associated with increased risk of admission to hospital because of CHF in a well‐characterized, community‐based cohort of Type 2 diabetic patients without prevalent CHF. Methods A cohort study of all patients in the Kaiser Permanente Medical Care Program with Type 2 diabetes (Kaiser Permanente Northern California Diabetes Registry) who initiated any diabetes pharmacotherapy (n = 23 440) between October 1999 and November 2001. Only patients initiating single new therapies (‘new users’) were included to reduce confounding and create mutually exclusive exposure groups. We constructed Cox proportional hazards models (with sulphonylureas initiators specified as the reference group) to evaluate the impact of initiating new diabetes therapies on time‐to‐incident admission to hospital because of CHF, defined by primary hospital discharge diagnosis. Results Patients initiated pioglitazone (15.2%), sulphonylureas (25.3%), metformin (50.9%), and insulin (8.6%) alone, or as additions to pre‐existing or maintained therapies. Three hundred and twenty admissions for CHF were observed during the follow‐up (mean 10.2 months) after drug initiation. Relative to patients initiating sulphonylureas, there were no significant increases in the incidence of hospitalization for CHF in those initiating pioglitazone [hazard ratio (HR) = 1.28; 95% confidence interval (CI): 0.85–1.92] after adjusting for demographic, behavioural and clinical factors. There was a significantly higher incidence among those initiating insulin (HR = 1.56; 95% CI: 1.00–2.45) and lower incidence among those initiating metformin (HR = 0.70; 95% CI: 0.49–0.99). Conclusions This study of patients with Type 2 diabetes failed to find evidence that short‐term pioglitazone use was associated with an elevated risk of hospitalization for CHF relative to the standard, first‐line diabetes therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2005.01704.x

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 90

Metadata

Authors
Karter, A. J., Ahmed, A. T., Liu, J., Moffet, H. H., & Parker, M. M.
Venue
Diabetic Medicine
Publisher
Wiley
Published
2005-07-13
Volume
22
Issue
8
Pages
986-993
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W2154572400
Cited by
90
References
9
FWCI
7.48
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pioglitazone initiation and subsequent hospitalization for congestive heart failure. https://app.cochat.ai/papers/10.1111/j.1464-5491.2005.01704.x
The paper
Karter, A. J., Ahmed, A. T., Liu, J., Moffet, H. H., & Parker, M. M. (2005). Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2005.01704.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.